In This Article:
Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio
Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health
Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team
DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and scale. This expansion also further supports the Company's consumer-led innovation pipeline.
To lead this expanded office, the Company has appointed Abbie Lennox as Executive Vice President and Chief Scientific Officer. Ms. Lennox is an experienced consumer self-care leader with a successful track record of driving regulatory excellence, product life cycle management and new product innovation across well-known consumer self-care portfolios.
President and CEO Patrick Lockwood-Taylor commented, "Expanding our Chief Scientific Office by bringing quality, regulatory and innovation excellence under one umbrella is an important step in our evolution and blueprint to build One Perrigo. Abbie is the right person to lead this new coordinated effort, drive new consumer-led innovation that consumers trust and advance our consumer self-care vision."
Ms. Lennox joins Perrigo from Bayer where she served as Executive Board Member and Chief Trust and Science Officer, responsible for leading the regulatory, medical affairs, safety and quality teams. She led multiple innovation launches – both product and claim-based – across global product categories, including cardio, digestive health, allergy, cough, cold, pain, dermatology, women's health, VMS (Vitamins, Minerals and Supplements) and Rx-to-OTC switches. Specifically, Ms. Lennox provided scientific leadership for the U.S. Rx-to-OTC switch for Astepro®, emphasizing consumer-centric claims supported by robust medical insights. She also led the introduction of Rennie® Gum, the first European OTC chewing gum for digestive health, by navigating rigorous clinical and registration requirements while prioritizing consumer experience. Prior to her time at Bayer, she served in regulatory affairs leadership roles with Reckitt Benckiser, where she advanced their regulatory approach to pipeline delivery across multiple health and wellness brands. Ms. Lennox holds a First Class BSc (Honors) degree in Biomedical Science and Chemistry from De Montfort University.